Medea Inc. Partners With CalOptima Health To Distribute 100,000 Units of Naloxone To Harm Reduction Organizations in Southern California
13 Agosto 2024 - 10:00AM
Business Wire
Naloxone, the opioid reversal agent, to be
distributed locally to combat illicit fentanyl and other
opioid-related deaths gripping Southern California
Medea Inc., a medical products and pharmaceutical distribution
company, is helping lead efforts to provide 100,000 units of
naloxone nasal spray to Orange County harm reduction organizations
to combat the devastating impact of drug overdose deaths from
fentanyl and other synthetic opioids.
This life-saving drug was procured by CalOptima Health (Orange
County’s community-based health insurance plan for Medi-Cal
beneficiaries) through its Drive to Revive initiative launched in
2023. CalOptima Health has partnered with Medea to supply and
distribute naloxone throughout Orange County. Among the recipients
is Recovery Road, which will be distributing the donated naloxone
at a community wellness fair in Anaheim on August 29 from 5:30–8:30
p.m. (250 E. Center St., Anaheim, CA 92805).
Shipments of the naloxone began in July. The product will reach
those in need through community events in Anaheim, Buena Park,
Irvine, Newport Beach and other cities. In addition to Recovery
Road, harm reduction groups Fentanyl Solution, End Overdose and
Harm Reduction Circle will also receive allocations. CalOptima
Health-affiliated provider groups and community organizations are
eligible to receive free allocations of naloxone as well.
“The availability of naloxone and other reversal agents is
imperative to combating the effects of the nationwide opioid
epidemic,” said Shane K.M. Wood, executive director of Fentanyl
Solution. “Working through a diversified network of other
nonprofits and local businesses such as nightclubs, barbershops and
grocery stores, our goal is to make opioid reversal drugs as
accessible as a first-aid kit.”
“When it comes to the fentanyl scourge that is indiscriminately
poisoning and killing our families, friends and neighbors, everyone
is a first responder. Medea is committed to distributing all forms
of affordable naloxone in the ongoing battle against opioid-related
fatalities,” said Brandon Laidlaw, CEO of Medea Inc.
Poisoning by fentanyl is the leading cause of death for kids 17
years old and younger in Orange County. Each week, illicit fentanyl
is responsible for approximately 110 deaths statewide. Access to
crucial treatments such as naloxone is often the difference between
life and death.
To learn more about upcoming distribution events and
availability of naloxone in Southern California communities, email
info@medeamp.com.
About Medea Inc.:
Medea Inc., established in 2014 and headquartered in the Silicon
Valley Economic Region and Orange County, California, specializes
in the distribution of naloxone and other FDA-approved medical
products to all levels of government, healthcare and retail
channels. Medea also offers full-service product fulfillment
services. For more information regarding Medea and its opioid
reversal drugs, please visit https://medeausa.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240813372923/en/
Marie Moretti Chief Marketing Officer Medea Inc. (925) 425-9282
marie@medeamp.com